Guardant Health Inc (GH) concluded trading on Thursday at a closing price of $41.68, with 4.02 million shares of worth about $167.47 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 76.61% during that period and on May 08, 2025 the price saw a gain of about 4.88%. Currently the company’s common shares owned by public are about 123.65M shares, out of which, 117.60M shares are available for trading.
Stock saw a price change of -14.71% in past 5 days and over the past one month there was a price change of 4.70%. Year-to-date (YTD), GH shares are showing a performance of 36.43% which increased to 120.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.01 but also hit the highest price of $52.92 during that period. The average intraday trading volume for Guardant Health Inc shares is 2.35 million. The stock is currently trading -7.44% below its 20-day simple moving average (SMA20), while that difference is down -4.51% for SMA50 and it goes to 20.03% higher than SMA200.
Guardant Health Inc (NASDAQ: GH) currently have 123.65M outstanding shares and institutions hold larger chunk of about 96.96% of that.
The stock has a current market capitalization of $5.16B and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$3.38 in the same period. It has Quick Ratio of 3.76. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GH, volatility over the week remained 7.93% while standing at 6.65% over the month.
Stock’s fiscal year EPS is expected to rise by 22.03% while it is estimated to increase by 13.85% in next year. EPS is likely to grow at an annualized rate of 19.66% for next 5-years, compared to annual growth of -33.61% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on April 10, 2025 offering an Outperform rating for the stock and assigned a target price of $55 to it. Coverage by Barclays stated Guardant Health Inc (GH) stock as an Overweight in their note to investors on January 23, 2025, suggesting a price target of $60 for the stock. On June 28, 2024, Guggenheim Upgrade their recommendations, while on June 03, 2024, Jefferies Resumed their ratings for the stock with a price target of $32. Stock get a Buy rating from Craig Hallum on April 24, 2024.
